Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/25878
Title: Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
Authors: B. Ongphiphadhanakul
N. Piaseu
S. Sae Tung
L. Chailurkit
R. Rajatanavin
Mahidol University
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 15-Feb-2000
Citation: Maturitas. Vol.34, No.2 (2000), 179-184
Abstract: Objectives: Estrogen deficiency is the most common cause of postmenopausal osteoporosis and estrogen replacement is well known to retard postmenopausal bone loss. Calcium supplement alone is generally considered to be insufficient for the prevention of bone loss associated with estrogen deficiency while the role of calcitriol is unclear. In the present study we examined the efficacy different doses of estrogen or calcitriol in the prevention of postmenopausal bone loss in Thais. Methods: The subjects consisted of 146 Thai women no more than 6 years postmenopausal. The subjects were randomly allocated to receive 750 mg supplemental calcium alone, calcium and conjugated equine estrogen (CEE) at 0.3 or 0.625 mg, calcium and calcitriol at 0.25 or 0.5 μg daily. Those receiving CEE also took 5 mg medrogestone for 12 days each month. BMD at L2-4 and femoral neck were measured at baseline 1 year and 2 years after treatments. Data were expressed as mean±S.E. Results: Subjects on supplemental calcium alone had approximately 2.5% decreases in L2-4 (P<0.05) and femoral BMD (P<0.01) at 2 years. CEE (0.3 mg) resulted in 3.20±1.2% increase in vertebral BMD (P<0.05) while no significant change in BMD was demonstrated at the femoral neck. Likewise, 0.625 mg of CEE induced 5.4±1.4% increase in vertebral BMD at 2 years (P<0.001) without change in the femoral BMD. In regard to calcitriol, no significant change in vertebral or femoral BMD was demonstrated with either 0.25 or 0.5 μg calcitriol. Conclusion: We concluded that calcitriol is effective in the prevention of early postmenopausal bone loss in Thais. It represents an option for the prevention of osteoporosis in postmenopausal women who are contraindicated for estrogen replacement. © 2000 Elsevier Science Ireland Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033973264&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/25878
ISSN: 03785122
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.